ladarixin

Ladarixin is an orally bioavailable small molecule that acts as a dual, non-competitive allosteric inhibitor of the C-X-C motif chemokine receptors 1 (CXCR1) and 2 (CXCR2), which are interleukin-8 (IL-8) receptors. By blocking these receptors, ladarixin inhibits CXCR1/2-mediated signaling pathways involved in inflammation and immune cell recruitment. This mechanism reduces neutrophil and myeloid-derived suppressor cell migration and activity in inflammatory environments such as the tumor microenvironment or pancreatic islets. Ladarixin has been primarily developed for type 1 diabetes to preserve pancreatic beta-cell function by preventing immune-mediated destruction but has also been investigated for insulin resistance, certain cancers (including advanced non-small cell lung cancer), obesity/type 2 diabetes, bullous pemphigoid, malignant melanoma, spinal cord injuries, and neutrophilic airway diseases. The drug was developed by Dompe Farmaceutici.

Brand names

Meraxin

Other names

ladarixina849776-05-2